AstraZeneca (AZN) vs Regeneron Pharmaceuticals (REGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Regeneron Pharmaceuticals (REGN) has outperformed AstraZeneca (AZN) over the past year, gaining 27.2% versus a loss of 6.8%. Over five years, REGN leads with a +34.1% price change compared with +32.9% for AZN. AstraZeneca is the larger company by market cap ($248.33 billion vs $76.40 billion), about 3.3 times the size.
On valuation, Regeneron Pharmaceuticals trades at a lower forward P/E (12.1x vs 13.8x for AstraZeneca). AstraZeneca offers the higher dividend yield (2.02% vs 0.49%). Regeneron Pharmaceuticals converts more of its revenue into profit, with a net margin of 31.4% versus 17.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AZN | REGN |
|---|---|---|
| Share price | $160.12 | $742.12 |
| Market cap | $248.33B | $76.40B |
| 1-day change | +0.95% | +0.46% |
| YTD return | -12.91% | -3.85% |
| 1-year return | -6.77% | +27.24% |
| 5-year return | +32.95% | +34.14% |
| P/E ratio (TTM) | 23.93 | 18.35 |
| Forward P/E | 13.85 | 12.07 |
| EPS (TTM) | $6.69 | $40.44 |
| Dividend yield | 2.02% | 0.49% |
| Annual dividend | $3.23 | $3.64 |
| Revenue (latest FY) | $58.74B | $14.34B |
| Revenue growth (YoY) | +8.63% | +0.99% |
| Net income (latest FY) | $10.22B | $4.50B |
| Gross margin | 81.90% | — |
| Operating margin | 23.40% | 24.95% |
| Net margin | 17.41% | 31.41% |
| 52-week high | $212.71 | $859.34 |
| 52-week low | $153.41 | $541.00 |
| Distance from 52-week high | -24.72% | -13.64% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +31.99% | +15.38% |
| Average volume | 3.41M | 741.47K |
| Shares outstanding | 1.55B | 101.14M |
| Employees | 96,100 | 15,410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AstraZeneca is about 3.3 times larger than Regeneron Pharmaceuticals by market value ($248.33B vs $76.40B).
- REGN has outperformed AZN by 34.0 percentage points over the past year.
- AstraZeneca trades at a higher earnings multiple (23.9x vs 18.4x trailing P/E).
- AstraZeneca offers a meaningfully higher dividend yield (2.02% vs 0.49%).
- Regeneron Pharmaceuticals is more profitable, keeping 31.4 cents of every revenue dollar as net income versus 17.4 cents for AstraZeneca.
- AstraZeneca grew revenue faster in its latest fiscal year (+8.63% vs +0.99%).
About AstraZeneca
AZN stock →AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
Health Care · Biotechnology: Pharmaceutical Preparations · 96,100 employees
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
AZN vs REGN FAQ
Which is bigger, AstraZeneca or Regeneron Pharmaceuticals?
AstraZeneca (AZN) is larger, with a market capitalization of $248.33B compared with $76.40B for Regeneron Pharmaceuticals (REGN).
Which stock has performed better over the past year, AZN or REGN?
REGN returned +27.24% over the past 12 months, compared with -6.77% for AZN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AZN or REGN?
REGN has the lower trailing P/E at 18.4, versus 23.9 for AZN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, AstraZeneca or Regeneron Pharmaceuticals?
AstraZeneca has the higher yield at 2.02%, compared with 0.49% for Regeneron Pharmaceuticals.
Are AstraZeneca and Regeneron Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.